Japanese researchers found that Eisai's anti-clotting drug atopaxar reduced the incidence of heart problems more than placebo in two midstage trials involving patients with either acute coronary syndrome or high-risk coronary artery disease. One study author noted that the trials were not designed to prove efficacy and that the overall number of cardiovascular events was low.

Full Story:

Related Summaries